logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Apellis Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 27

% Expired Patents = 3.7


Trademarks = 9

Forward Citations = 188

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal Cedric Francois (25 out of 43 patents)

silverMedal Pascal Deschatelets (23 out of 31 patents)

bronzeMedal Federico Grossi (5 out of 5 patents)

4.  Patrick Johnson (4 out of 4 patents)

5.  Carolina Vega (4 out of 4 patents)

6.  Monica Gerber (3 out of 4 patents)

7.  Lukas Scheibler (3 out of 18 patents)

8.  Paul Olson (3 out of 24 patents)

9.  Christian Mueller (2 out of 27 patents)

10.  Zhouning Zhang (1 out of 1 patent)


Core Competencies:
Viral Vector Therapy
Complement Inhibition
Compstatin Analogs
Dosing Regimens
Chronic Disorders
Combination Therapy
RNA Therapeutics
Complement-Mediated Disorders
Detection of Drusen
Cell-Reactive Analogs
Targeted Therapies
Neuropathic Pain

27 patents:

1. 12741036 - VIRAL VECTOR THERAPY (2026-09-22),
2. 12458695 - Dosing regimens and related compositions and methods (2025-11-04),
3. 12290566 - Dosing regimens and related compositions and methods (2025-05-06),
4. 12251395 - RNAS for complement inhibition (2025-03-18),
5. 11903994 - Dosing regimens (2024-02-20),
6. 11844841 - Dosing regimens and related compositions and methods (2023-12-19),
7. 11712460 - Methods of treating chronic disorders with complement inhibitors (2023-08-01),
8. 11661441 - Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof (2023-05-30),
9. 11510939 - RNAs for complement inhibition (2022-11-29),
10. 11407789 - Cell-penetrating compstatin analogs and uses thereof (2022-08-09),
11. 11338013 - Combination therapy for C3 inhibition (2022-05-24),
12. 11292815 - Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods (2022-04-05),
13. 11291407 - Detection of high risk drusen (2022-04-05),
14. 11040107 - Dosing regimens and related compositions and methods (2021-06-22),
15. 11013782 - Methods of treating chronic disorders with complement inhibitors (2021-05-25),
Company Overview
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company based in Waltham, MA, focused on developing innovative therapies for patients with rare diseases. The company specializes in complement inhibition, a critical area of research aimed at addressing various autoimmune and inflammatory conditions. Apellis is dedicated to advancing its pipeline of novel treatments that target the underlying mechanisms of disease, thereby improving patient outcomes and quality of life.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Apellis Pharmaceuticals, Inc. USPTO Patent Assignee Logo
27 Patents

#58 in Waltham, MA

#740 in Massachusetts

#12,432 in US

#24,046 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Apellis Pharmaceuticals, Inc.

Forward Citations = 188

10 inventors:

goldMedal Cedric Francois (25 out of 43 patents)

silverMedal Pascal Deschatelets (23 out of 31 patents)

bronzeMedal Federico Grossi (5 out of 5 patents)

4.  Patrick Johnson (4 out of 4 patents)

5.  Carolina Vega (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Apellis Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/apellis-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…